Corinne Clifford

Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i> -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> Fusion

Zofia Piotrowska, Hideko Isozaki, Jochen K. Lennerz et al. · Cancer Discovery · 2018 · 434 citations

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

Justin F. Gainor, Giuseppe Curigliano, Dong‐Wan Kim et al. · The Lancet Oncology · 2021 · 428 citations · Full text

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

Vivek Subbiah, Mimi I. Hu, Lori J. Wirth et al. · The Lancet Diabetes & Endocrinology · 2021 · 330 citations

Medicine, Thyroid Disease, Pathology +8

Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC).

Justin F. Gainor, Dae Ho Lee, Giuseppe Curigliano et al. · Journal of Clinical Oncology · 2019 · 108 citations

Immunology, Pathology, Ret Fusions +16

Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC).

Justin F. Gainor, Giuseppe Curigliano, Dong‐Wan Kim et al. · Journal of Clinical Oncology · 2020 · 74 citations

Ret Fusion+ Nsclc, Medicine, Cancer Management +14